Literature DB >> 26186988

Risk factors for recurrent primary sclerosing cholangitis after liver transplantation.

Reena Ravikumar1, Emmanuel Tsochatzis2, Sophie Jose3, Michael Allison4, Anuja Athale5, Felicity Creamer6, Bridget Gunson7, Vikram Iyer7, Mansoor Madanur5, Derek Manas8, Andrea Monaco2, Darius Mirza7, Nicola Owen4, Keith Roberts7, Gourab Sen8, Parthi Srinivasan5, Stephen Wigmore8, Giuseppe Fusai2, Bimbi Fernando2, Andrew Burroughs2.   

Abstract

BACKGROUND & AIMS: The association between primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) is well recognised. However, the relationship between IBD and recurrent PSC (rPSC) is less well understood. We assessed the prevalence of rPSC and analysed the factors associated with rPSC post-liver transplantation and its influence on graft and patient survival.
METHODS: This is a UK multicentre observational cohort study across six of the seven national liver transplant units. All patients undergoing a first liver transplant for PSC between January 1 1990 and December 31 2010 were included. Prospectively collected liver transplant data was obtained from NHSBT and colitis data was retrospectively collected from individual units.
RESULTS: There were 679 (8.8%) first transplants for PSC. 347 patients (61.4%) had IBD, of which 306 (88.2%) had ulcerative colitis (UC). 81 (14.3%) patients developed rPSC and 37 (48.7%) of them developed graft failure from rPSC. Presence of UC post-liver transplant (HR=2.40, 95% CI 1.44-4.02) and younger age (HR=0.78, 95% CI 0.66-0.93) were the only factors significantly associated with rPSC. rPSC was associated with over a 4-fold increase in the risk of death (HR=4.71, 95% CI 3.39, 6.56) with 1, 5, and 10-year graft survival rates of 98%, 84%, and 56% respectively compared to 95%, 88%, and 72% in patients who did not develop rPSC.
CONCLUSION: The presence of UC post-liver transplant is associated with a significantly increased risk of rPSC. Furthermore, the presence of rPSC increases the rate of graft failure and death, with higher re-transplantation rates.
Copyright © 2015. Published by Elsevier B.V.

Entities:  

Keywords:  Colectomy; Liver transplantation; Patients and graft survival; Recurrent PSC; Ulcerative colitis

Mesh:

Year:  2015        PMID: 26186988     DOI: 10.1016/j.jhep.2015.07.005

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  20 in total

Review 1.  Guideline review: British Society of Gastroenterology/UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis.

Authors:  Alberto Nicoletti; James B Maurice; Douglas Thorburn
Journal:  Frontline Gastroenterol       Date:  2020-03-02

Review 2.  Role of colectomy in preventing recurrent primary sclerosing cholangitis in liver transplant recipients.

Authors:  Bettina M Buchholz; Panagis M Lykoudis; Reena Ravikumar; Joerg M Pollok; Giuseppe K Fusai
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

3.  Outcomes of liver retransplantation in patients with primary sclerosing cholangitis.

Authors:  Jacqueline B Henson; Yuval A Patel; Lindsay Y King; Jiayin Zheng; Shein-Chung Chow; Andrew J Muir
Journal:  Liver Transpl       Date:  2017-06       Impact factor: 5.799

4.  Differences in Phenotypes and Liver Transplantation Outcomes by Age Group in Patients with Primary Sclerosing Cholangitis.

Authors:  Jacqueline B Henson; Yuval A Patel; Julius M Wilder; Jiayin Zheng; Shein-Chung Chow; Lindsay Y King; Andrew J Muir
Journal:  Dig Dis Sci       Date:  2017-04-08       Impact factor: 3.199

5.  Single Topic Conference on Autoimmune Liver Disease from the Canadian Association for the Study of the Liver.

Authors:  Aldo J Montano-Loza; Jessica R Allegretti; Angela Cheung; Maryam Ebadi; David Jones; Nanda Kerkar; Cynthia Levy; Sumera Rizvi; John M Vierling; Fernando Alvarez; Wayne Bai; Susan Gilmour; Aliya Gulamhusein; Orlee Guttman; Bettina E Hansen; Sonya MacParland; Andrew Mason; Fernanda Onofrio; Pere Santamaria; Ashley Stueck; Mark Swain; Catherine Vincent; Amanda Ricciuto; Gideon Hirschfield
Journal:  Can Liver J       Date:  2021-11-11

Review 6.  Primary sclerosing cholangitis: review for radiologists.

Authors:  Matthew A Morgan; Rachita Khot; Karthik M Sundaram; Daniel R Ludwig; Rashmi T Nair; Pardeep K Mittal; Dhakshina M Ganeshan; Sudhakar K Venkatesh
Journal:  Abdom Radiol (NY)       Date:  2022-09-05

7.  Primary Sclerosing Cholangitis, Part 1: Epidemiology, Etiopathogenesis, Clinical Features, and Treatment.

Authors:  James H Tabibian; Ahmad H Ali; Keith D Lindor
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-05

8.  Recurrence of Primary Sclerosing Cholangitis After Liver Transplant in Children: An International Observational Study.

Authors:  Mercedes Martinez; Emily R Perito; Pamela Valentino; Cara L Mack; Madeleine Aumar; Annemarie Broderick; Laura G Draijer; Eleonora D T Fagundes; Katryn N Furuya; Nitika Gupta; Simon Horslen; Maureen M Jonas; Binita M Kamath; Nanda Kerkar; Kyung Mo Kim; Kaija-Leena Kolho; Bart G P Koot; Trevor J Laborda; Christine K Lee; Kathleen M Loomes; Tamir Miloh; Douglas Mogul; Saeed Mohammed; Nadia Ovchinsky; Girish Rao; Amanda Ricciuto; Alexandre Rodrigues Ferreira; Kathleen B Schwarz; Vratislav Smolka; Atsushi Tanaka; Mary E M Tessier; Venna L Venkat; Bernadette E Vitola; Marek Woynarowski; Melissa Zerofsky; Mark R Deneau
Journal:  Hepatology       Date:  2021-09-09       Impact factor: 17.298

9.  Intestinal CCL25 expression is increased in colitis and correlates with inflammatory activity.

Authors:  Palak J Trivedi; Tony Bruns; Stephen Ward; Martina Mai; Carsten Schmidt; Gideon M Hirschfield; Chris J Weston; David H Adams
Journal:  J Autoimmun       Date:  2016-02-09       Impact factor: 7.094

10.  Increased Cumulative Incidence of Dermatomyositis in Ulcerative Colitis: a Nationwide Cohort Study.

Authors:  Chia-Chun Tseng; Shun-Jen Chang; Wei-Ting Liao; Ya-Ting Chan; Wen-Chan Tsai; Tsan-Teng Ou; Cheng-Chin Wu; Wan-Yu Sung; Ming-Chia Hsieh; Jeng-Hsien Yen
Journal:  Sci Rep       Date:  2016-06-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.